ClinicalTrials.gg
Not yet recruitingNCT07722767Updated Oct 28, 2026

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

A Phase 1 interventional study of CLN-049 and Azacitidine in AML (Acute Myeloid Leukemia), sponsored by Cullinan Therapeutics Inc.. Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Cullinan Therapeutics Inc. · Phase 1, Interventional, and Treatment

Updated Oct 28, 2026Eligibility revised2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States — 311 open to participants now, 465 under way, 24 of them phase 3. Leukemia, Myeloid, Acute · United States.

Planned enrollment
369th of 1,907
90 · median 35
Started
2026
with 72 others
Phase 1
772 of 2,137
130 open now
Primary completion
2027-09
later than 246 of 463 live
Registered
2,125th of 2,137
by date

Among the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, this one is the 369th largest by planned enrollment of the 1,907 interventional ones that give a count, is one of 73 that started in 2026, is one of 772 in phase 1, reaches primary completion later than 246 of the 463 other live ones, and was the 2,125th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

311 of the 2,137 studies in Leukemia, Myeloid, Acute with a site in United States are open now. Recruiting first, the newest first:

306 more — sign in →

All 311 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,137 studies in Leukemia, Myeloid, Acute with a site in United States, or all of them as a file.
02

Study summary

A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.

03

Conditions studied

  • AML (Acute Myeloid Leukemia)

Keywords

  • Newly diagnosed AML
  • TP53-mutated AML
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients aged ≥ 18 years of age with newly diagnosed, previously untreated AML (including MDS/AML)

    • De novo and secondary AML are eligible
    • Patients with molecularly defined AML subtypes (including but not limited to FLT3-mutated, IDH1/2-mutated, NPM1-mutated, KMT2A rearranged, and TP53-mutated AML) are eligible
    • Patients with TP53-mutated AML are eligible
  2. White blood cell (WBC) count at the time of C1D1 ≤ 20,000/μL
  3. Patients must have previously untreated AML; No prior AML treatment other than hydroxyurea for cytoreduction and one dose of intrathecal chemotherapy for suspected central nervous system (CNS) involvement (that is ruled out) is allowed. Prior therapy for MDS is allowed except for hypomethylating agents and venetoclax.
  4. (ECOG) performance status is 0 to 2
  5. The patient's laboratory values meet the following criteria:

    1. (CrCl) ≥ 45 mL/min;
    2. Total ≤ 1.5 × (ULN)
    3. (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN

Exclusion criteria

Exclusion Criteria:

  1. Patients willing and able to receive standard intensive chemotherapy.
  2. Isolated myeloid sarcoma (meaning, patients must have blood or marrow involvement with AML to enter the study).
  3. Diagnosis of acute promyelocytic leukemia or PML:RARA-positive AML.
  4. Chronic myeloid leukemia in blast phase or AML with BCR:ABL1.
  5. Mixed phenotype acute leukemia or acute leukemia of ambiguous lineage.
  6. Active CNS involvement by AML.
  7. Signs of leukostasis requiring urgent therapy.
  8. Prior organ allograft, or prior hematopoietic stem cell transplant within the last 12 months, or with active graph-versus-host disease.
  9. Treatment with systemic therapy or other immune-suppressive drugs ≤ 14 days prior to the first dose of CLN-049.
  10. Patients with concomitant second requiring active treatment in the past 12 months, or if additional therapy is required or anticipated during study participation.
  11. Patients with any active disease or a history of known or suspected autoimmune disease, or history of a syndrome that requires systemic corticosteroids or medications
  12. Active uncontrolled infection until infection is treated and brought under control.
  13. Has a history of, or a positive test for (HIV) 1/2 or primary immunodeficiency disease such as HIV.
  14. Known history of , (HCV) infection, or acute hepatitis A.
  15. Active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
  16. Patients who have received an agent (for any indication) within 5 half-lives of the agent and until toxicity from this has resolved to Grade 1 or less
  17. History of the following events in conjunction with prior treatment with immunotherapy: Grade 3 or greater neurotoxicity, ocular toxicity, pneumonitis, myocarditis, or colitis; liver dysfunction meeting the laboratory criteria for Hy's Law.
  18. within 28 days of the first dose of CLN-049, during treatment, and until the end of last dose of CLN-049.
  19. corrected for heart rate using Fridericia's formula (QTcF) of ≥ 480 milliseconds.
  20. Patient has a history of drug-related anaphylactic reactions to any components of CLN-049, or a history of Grade 4 anaphylactic reaction to any bispecific molecule or monoclonal antibody therapy.
  21. Known history of prior human anti-human antibody response.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Part A: Dose Escalation

    Newly diagnosed AML patients treated with standard of care azacitidine and venetoclax in addition to CLN-049 in dose escalation cohorts

    Drug: CLN-049 · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    Part B: Dose Expansion

    Newly diagnosed AML patients treated with standard of care azacitidine and venetoclax in addition to CLN-049 at a dose determined in Part A (Dose Escalation)

    Drug: CLN-049 · Drug: Azacitidine · Drug: Venetoclax

Interventions

  • DrugCLN-049

    CLN-049 will be initiated using two step-up doses (SUDs), followed by the first target dose (TD) one week later, and weekly thereafter.

  • Azacitidine 75 mg/m2 will initially be administered sub-cutaneous or intravenous on days 1 through 7 of a 28-day cycle

  • Venetoclax will initially be administered orally on days 1 through 28 of a 28-day cycle and then reduced to days 1 through 14 in consolidation cycles.

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclax

    Safety assessments include: body measurements, vital signs, physical exam, EGOG (measure of patient function in terms of self-care, daily activity, and physical ability) performance status, lab assessments, ECGs, and ECHO/MUGA (tests to evaluate heart function)

    Time frame: 48 weeks

  2. Determine recommended dose/schedule of CLN-049 in combination with azacitidine and venetoclax

    Time frame: 48 weeks

07

Study locations

5 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2027, 11 months later.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 11 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 23, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Aug 31, 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 United States)
  • University of Miami Health System · Miami, United States
  • Emory University Hospital · Atlanta, United States
Oct 28, 2026
Eligibility
1 inclusion criterion edited, 3 added, 1 removed; 1 exclusion criterion added
What changed in the criteria
Inclusion criteria
  • RemovedPatients are not candidates for intensive induction chemotherapy because they are either unfit or otherwise clinically unsuitable for anthracycline/ cytarabine-based induction therapy
  • AddedDe novo and secondary AML are eligible
  • AddedPatients with molecularly defined AML subtypes (including but not limited to FLT3-mutated, IDH1/2-mutated, NPM1-mutated, KMT2A rearranged, and TP53-mutated AML) are eligible
  • AddedPatients with TP53-mutated AML are eligible
  • EditedPatients must have previously untreated AML; No prior AML treatment other than hydroxyurea for cytoreduction and one dose of intrathecal chemotherapy for suspected central nervous system (CNS) involvement (that is permitted up to C1D1ruled out) is allowed. Prior therapy for MDS is allowed except for hypomethylating agents and venetoclax.
Exclusion criteria
  • AddedPatients willing and able to receive standard intensive chemotherapy.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    2 sites added
    Show 2 added (2 United States)
    • University of Miami Health System · Miami, United States
    • Emory University Hospital · Atlanta, United States
    Eligibility 1 inclusion criterion edited, 3 added, 1 removed; 1 exclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • RemovedPatients are not candidates for intensive induction chemotherapy because they are either unfit or otherwise clinically unsuitable for anthracycline/ cytarabine-based induction therapy
    • AddedDe novo and secondary AML are eligible
    • AddedPatients with molecularly defined AML subtypes (including but not limited to FLT3-mutated, IDH1/2-mutated, NPM1-mutated, KMT2A rearranged, and TP53-mutated AML) are eligible
    • AddedPatients with TP53-mutated AML are eligible
    • EditedPatients must have previously untreated AML; No prior AML treatment other than hydroxyurea for cytoreduction and one dose of intrathecal chemotherapy for suspected central nervous system (CNS) involvement (that is permitted up to C1D1ruled out) is allowed. Prior therapy for MDS is allowed except for hypomethylating agents and venetoclax.
    Exclusion criteria
    • AddedPatients willing and able to receive standard intensive chemotherapy.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07722767
Lead sponsor
Cullinan Therapeutics Inc.
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Timna Serino
Contact
ClinOps@cullinantx.com
617-410-4650

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion